Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711294 · ClinicalTrials.gov registry record · NA
Evaluation of PCLs Using Three EUS-FNA Needles
A NA study of Pancreatic Cystic Lesions, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 8
- Study locations
NCT01711294: Completed NA study of Pancreatic Cystic Lesions, sponsored by Boston Scientific Corporation.
NCT01711294 is a NA study of Pancreatic Cystic Lesions that has completed, run by Boston Scientific Corporation. The registered enrollment target is 250 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01711294, a NA study of Pancreatic Cystic Lesions, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 8
- Study locations
Study Summary
To document impact of EUS-FNA needle size and flexibility on effectiveness of pancreatic cystic lesions (PCL) aspiration, on ability to obtain sufficient material for standard diagnostic testing, and on diagnostic accuracy of EUS-FNA aspirate for differentiation of mucinous (pre-malignant) and non-mucinous cysts.
Primary Outcome
Volume of aspirated cyst fluid as a function of estimated maximal volume, based on pre-aspiration EUS measure of cyst diameter (s) (% aspiration of total estimated volume)
Conditions Studied
Interventions
- DEVICE 19 G Flex Needle
- DEVICE 22 G Needle
- DEVICE 19 G Needle
Study Locations (8)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Other
- Changhai Hospital - Shanghai
- Asian Institute of Gastroenterology - Hyderabad
Arizona
- Mayo Clinic - Scottsdale
Florida
- Mayo Clinic - Jacksonville
Indiana
- Indiana University Medical Center - Indianapolis
New York
- New York Presbyterian Hospital/Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2013-01-08 |
| Est. Completion | 2019-12-18 |
| Phase | NA |
What the finished NCT01711294 record still lists
NCT01711294 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Pancreatic Cystic Lesions appearing as the primary indexed condition, and to 3 interventions - of which 19 G Flex Needle is the first listed.
NCT01711294 lists 8 locations in 6 states (Massachusetts, Other, Arizona).
Frequently Asked Questions
What is clinical trial NCT01711294 about?
NCT01711294 is a clinical study titled "Evaluation of PCLs Using Three EUS-FNA Needles". To document impact of EUS-FNA needle size and flexibility on effectiveness of pancreatic cystic lesions (PCL) aspiration, on ability to obtain sufficient material for standard diagnostic testing, and on diagnostic accuracy of EUS-FNA aspirate for differentiation of mucinous (pre-malignant) and non-m...
What is the current status of trial NCT01711294?
This trial is currently completed. It is a NA study. The enrollment target is 250 participants. The study started on 2013-01-08. Estimated completion is 2019-12-18.
What conditions does trial NCT01711294 study?
This clinical trial studies the following conditions: Pancreatic Cystic Lesions.
What interventions are being tested in trial NCT01711294?
The interventions under investigation include: 19 G Flex Needle (DEVICE), 22 G Needle (DEVICE), 19 G Needle (DEVICE).
Who is sponsoring clinical trial NCT01711294?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01711294 being conducted?
This trial has 8 study locations across Arizona, Florida, Indiana, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cystic Lesions
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01711294's enrollment target sits among peer trials
250 410th of 2000 higher than 1,567 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI